Planned sale

Myriad Genetics (MYGN): Director filed to sell ~$34K

Davis Mark Steven, Director at Myriad Genetics, filed to sell ~$34K of Myriad Genetics shares.

~$34K
planned to sell · 6,100 shares, around Nov 18, 2026
Planned for
Nov 18, 2026
Notice filed
Nov 18, 2026

What stands out in this filing

  • The planned sale is less than 0.01% of the company's shares outstanding.
  • How the shares were acquired, per the notice: Restricted Stock Vesting.
  • The notice says the shares were received as pay (stock awards or options).
  • Broker named on the notice: Fidelity Brokerage Services LLC.
  • A Form 144 announces a sale; the Form 4 that follows shows whether it took place, at what price.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 6, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 6, 2026, Myriad Genetics, Inc. (the “Company”) entered into a Separation Agreement and Release of Claims (the “Separation Agreement”) with Brian Donnelly, the Company’s former Chief Commercial Officer.”
  2. Oct 19, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
  3. Oct 27, 20265% stakeBlackRock Portfolio Management LLC reported a passive stake (13G) of 8.6%
  4. Nov 4, 2026Company filing · Form 8-K · ResultsReported its results
  5. Nov 6, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 6, 2026, the Compensation and Human Capital Committee (the “ Committee ”) of the Board of Directors (the “ Board ”) of Myriad Genetics, Inc. (the “ Company ”) approved one-time equity awards in the form of stock options (the “ Retention Option Awards ”) for certain executive officers of the Company, including its named executive officers, in order to promote the retention and continuity of the Company’s…”
  6. Nov 16, 20265% stakeVestal Point Capital, LP reported a passive stake (13G)
  7. Nov 18, 2026InsiderDirector sold ~$34K of MYGN shares in the open market
View the official recordSEC Form 144

How to read SEC Form 144

Form 144 is a notice that a company insider plans to sell shares. It is filed when the sell order is placed, so it announces a planned sale and does not prove that the sale took place.

Full guide: What is an SEC Form 144?

What else is on file for Myriad Genetics

For Myriad Genetics, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MYGN page.

How this filing works

Explore the data

Common questions

Which Myriad Genetics (MYGN) insider traded, and how much?

Davis Mark Steven, Director at Myriad Genetics, filed to sell ~$34K of Myriad Genetics shares. 6,100 shares, Form 144 notice of a planned sale.

When did it happen, and when was it made public?

Planned for: Nov 18, 2026. Notice filed: Nov 18, 2026.

What stands out in this filing?

The planned sale is less than 0.01% of the company's shares outstanding. How the shares were acquired, per the notice: Restricted Stock Vesting. The notice says the shares were received as pay (stock awards or options).

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 144, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Myriad Genetics recently?

For Myriad Genetics, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the MYGN page.

Does this mean MYGN stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Myriad Genetics

Everything OQRO holds on this company is on its MYGN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data